MHC-I genotype and tumor mutational burden predict response to immunotherapy AM Goodman et al, Genome Medicine, May 19, 2020

Hot Topics of the Day|PHGKB


Last Posted: May 21, 2020

---

• MHC-I genotype and tumor mutational burden predict response to immunotherapy
  AM Goodman et al, Genome Medicine, May 19, 2020
• The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
  Crumbaker Megan et al. Cancers 2020 May 12(5)
• Development and validation of a five-immune gene prognostic risk model in colon cancer.
  Chen Haitao et al. BMC cancer 2020 May 20(1) 395
• Immune-related adverse events of checkpoint inhibitors
  MR Casals et al, Nature Rev did Primers
• Radiomics and deep learning in lung cancer.
  Avanzo Michele et al. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2020 May
• Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?
  RB Corcoran et al, JAMA Oncology, May 7, 2020
• Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
  Yu Hui et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 14(1) 25-36
• Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.
  Pallocca Matteo et al. Journal of translational medicine 2019 17(1) 131
• What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
  Bravaccini Sara et al. Lung cancer (Amsterdam, Netherlands) 2019 132152-153
• Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
  Shi Yuankai et al. EBioMedicine 2020 Apr 54102731

more